Retatrutide OXY-RETA (15 mg) OxyPharma

Catalogue entry: Retatrutide OXY-RETA OxyPharma. Labelled content: 15 mg. Listed pack: 1 vial. The amount identifies labelled product content, not an administration dose.

Identity and mechanism

Retatrutide, development code LY3437943, is a peptide agonist at GIP, GLP-1 and glucagon receptors. Its three-target profile differs from the dual GIP/GLP-1 activity of Tirzepatide and the GLP-1 activity of Semaglutide. Counting receptors alone does not rank effectiveness, tolerability or suitability for an individual.

What the research measured

Jastreboff and colleagues published a phase II obesity trial in the New England Journal of Medicine in 2023. The later TRIUMPH-1 phase III publication appeared online in September 2026. These clinical programmes concern specified formulations and participant groups. They should not be reduced to bodybuilding claims or transferred automatically to a differently sourced product.

Sporting claims and limitations

In physique discussions, weight change is often treated as equivalent to fat loss with preserved strength. Scale weight, fat mass, lean mass and physical performance are separate outcomes. Gastrointestinal adverse effects were part of the clinical safety findings; long-term benefit-risk interpretation also depends on the population, accompanying conditions and complete evidence. More targets do not imply fewer risks.

Product identity and documentation

The options above describe labelled product content, not a clinical regimen. Check substance identity, formulation and batch documentation independently. A supplier vial is not authenticated by carrying a trial compound's name. A paediatric investigation-plan record is likewise different from a marketing authorisation. Product-specific records are needed before any approval or pharmaceutical-equivalence claim can be made.